Sequential or CombinaTion Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial)
Latest Information Update: 22 Dec 2025
At a glance
- Drugs Naltrexone/bupropion (Primary) ; Orlistat (Primary) ; Phentermine/topiramate (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Acronyms STAY-LEAN
Most Recent Events
- 12 Dec 2025 Planned End Date changed from 31 Dec 2026 to 28 Apr 2028.
- 12 Dec 2025 Planned primary completion date changed from 31 Dec 2025 to 28 Apr 2027.
- 12 Dec 2025 Status changed from recruiting to active, no longer recruiting.